Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.5.2 (
NQO1
)
6,196
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Benzene is oxidized in the liver to produce a series of hydroxylated metabolites, including hydroquinone and
1,2,4-benzenetriol
. These metabolites are activated to toxic and genotoxic species in the bone marrow via oxidation by myeloperoxidase (MPO).
NAD(P)H:quinone oxidoreductase
(
NQO1
) is an enzyme capable of reducing the oxidized quinone metabolites and thereby potentially reducing their toxicities. We introduced the
NQO1
gene into the HL-60 cell line to create a high MPO-, high
NQO1
-expressing cell line, and tested its response in assays of benzene metabolite toxicity.
NQO1
expression reduced a class of hydroquinone- and benzenetriol-induced DNA adducts by 79-86%. The cytotoxicity and apoptosis caused by hydroquinone were modestly reduced, while protein binding was unchanged and the rate of glutathione depletion increased.
NQO1
's activity in reducing a class of benzene metabolite-induced DNA adducts may be related to its known activities in maintaining membrane-bound endogenous antioxidants in reduced form. Alternatively,
NQO1
activity may prevent the formation of adducts which result from polymerized products of the quinones. In either case, this protection by
NQO1
may be an important mechanism in the observation that a lack of
NQO1
activity affords an increased risk of benzene poisoning in exposed individuals [Rothman, N., et al. (1997) Cancer Res. 57, 2839-2842].
...
PMID:Modulation of the toxicity and macromolecular binding of benzene metabolites by NAD(P)H:Quinone oxidoreductase in transfected HL-60 cells. 1036 8